Skip to content
Open access · CC-BY via OpenAlex

Treatment of age-related macular degeneration

Chui Ming Gemmy Cheung, Tien Yin Wong

The Lancet · 2013 · ▲ 25 citations

Abstract

Age-related macular degeneration is the leading cause of blindness in developed countries.1Lim LS Mitchell P Seddon JM Holz FG Wong TY Age-related macular degeneration.Lancet. 2012; 379: 1728-1738Summary Full Text Full Text PDF PubMed Scopus (1274) Google Scholar Since the mid-2000s, intraocular injections of agents inhibiting vascular endothelial growth factor (VEGF) have become the mainstay of treatment for neovascular (wet) age-related macular degeneration.2Wong TY Liew G Mitchell P Clinical update: new treatments for age-related macular degeneration.Lancet. 2007; 370: 204-206Summary Full Text Full Text PDF PubMed Scopus (125) Google Scholar, 3Rosenfeld PJ Brown DM Heier JS et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431Crossref PubMed Scopus (4840) Google Scholar, 4Brown DM Kaiser PK Michels M et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1432-1444Crossref PubMed Scopus (3040) Google Scholar Emerging data from national registries show that blindness related to age-related macular degeneration started to fall when anti-VEGF treatment was introduced.5Cheung N Wong TY Changing trends of blindness: the initial harvest from translational public health and clinical research in ophthalmology.Am J Ophthalmol. 2012; 153: 193-195Summary Full Text Full Text PDF PubMed Scopus (18) Google Scholar However, three key questions remain unanswered for physicians, their patients, and policy makers. First, what is the most cost-effective drug? Two anti-VEGF agents are available: ranibizumab, which was approved by the US Food and Drug Administration, and bevacizumab, which is a cancer drug widely used off label.1Lim LS Mitchell P Seddon JM Holz FG Wong TY Age-related macular degeneration.Lancet. 2012; 379: 1728-1738Summary Full Text Full Text PDF PubMed Scopus (1274) Google Scholar Bevacizumab costs a fraction of ranibizumab, and is the main drug used in many non-reimbursed settings, such as in US practice.6Levinson DR Review of Medicare part B Avastin and Lucentis treatments for age-related macular degeneration. Department of Health and Human Services, Washington, DCSept 6, 2011http://oig.hhs.gov/oas/reports/region10/11000514.pdfDate: 2011Google Scholar A report6Levinson DR Review of Medicare part B Avastin and Lucentis treatments for age-related macular degeneration. Department of Health and Human Services, Washington, DCSept 6, 2011http://oig.hhs.gov/oas/reports/region10/11000514.pdfDate: 2011Google Scholar suggested that US Medicare could save more than US$1 billion within 2 years if bevacizumab replaced ranibizumab. Second, how often should injections be given? Initial clinical trials3Rosenfeld PJ Brown DM Heier JS et al.Ranibizumab for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1419-1431Crossref PubMed Scopus (4840) Google Scholar, 4Brown DM Kaiser PK Michels M et al.Ranibizumab versus verteporfin for neovascular age-related macular degeneration.N Engl J Med. 2006; 355: 1432-1444Crossref PubMed Scopus (3040) Google Scholar suggested that ranibizumab should be given monthly for the best visual outcome. In clinical practice, physicians and patients would obviously prefer injections with intervals of longer than 1 month, and alternative regimens (eg, as needed) have been proposed. However, whether such alternative regimens have acceptable results is unclear. Third, does long-term treatment have safety issues? Although anti-VEGF agents are injected in small quantities into the eye, concerns about systemic safety have been raised, including possible risk of stroke.7Curtis LH Hammill BG Shulman KA Cousins SW Risks of mortality, myocardial infarction, bleeding and stroke associated with therapies for age-related macular degeneration.Arch Ophthalmol. 2010; 128: 1273-1279Crossref PubMed Scopus (185) Google Scholar, 8Lim LS Cheung CMG Mitchell P Wong TY Emerging evidence concerning systemic safety of anti-VEGF agents—should ophthalmologists be concerned?.Am J Ophthalmol. 2011; 152: 329-331Summary Full Text Full Text PDF PubMed Scopus (51) Google Scholar In The Lancet, Usha Chakravarthy and colleagues report 2-year findings of the IVAN randomised controlled trial.9Chakravarthy U Harding SP Rogers CA et al.on behalf of the IVAN study investigatorsAlternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial.Lancet. 2013; (published online July 19.)http://dx.doi.org/10.1016/S0140-6736(13)61501-9Summary Full Text Full Text PDF Scopus (573) Google Scholar This trial, along with the US CATT trial,10The CATT Research GroupRanibizumab and bevacizumab for neovascular age-related macular degeneration.N Engl J Med. 2011; 364: 1897-1908Crossref PubMed Scopus (2166) Google Scholar, 11The CATT Research GroupRanibizumab and bevacizumab for neovascular age-related macular degeneration: two-year results.Ophthalmology. 2012; 119: 1388-1398Summary Full Text Full Text PDF PubMed Scopus (1446) Google Scholar attempts to answer these questions. In IVAN, adults with untreated neovascular age-related macular degeneration were randomly assigned to receive intravitreal injections of ranibizumab or bevacizumab in continuous (monthly) or discontinuous (as needed) regimens.12Chakravarthy U Harding SP et al.IVAN Study InvestigatorsRanibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial.Ophthalmology. 2012; 119: 1399-1411Summary Full Text Full Text PDF PubMed Scopus (658) Google Scholar Unfortunately, the results have not clarified the situation. For best corrected distance visual acuity—the primary outcome—bevacizumab was neither non-inferior nor inferior to ranibizumab (mean difference −1·37 letters in favour of ranibizumab, 95% CI −3·75 to 1·01; prespecified non-inferiority limit 3·5 letters).9Chakravarthy U Harding SP Rogers CA et al.on

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1016/s0140-6736(13)61580-9
Canonical
link ↗
Fetched
2026-10-20 MST

Cite this

APA
Cheung, C.M.G., &amp; Wong, T.Y. (2013). Treatment of age-related macular degeneration. <em>The Lancet</em>. https://doi.org/10.1016/s0140-6736(13)61580-9
Vancouver
Cheung CMG, Wong TY. Treatment of age-related macular degeneration. The Lancet. 2013. doi:10.1016/s0140-6736(13)61580-9.
BibTeX
@article{chui2013Treatm, title = {Treatment of age-related macular degeneration}, author = {Chui Ming Gemmy Cheung and Tien Yin Wong}, journal = {The Lancet}, year = {2013}, doi = {10.1016/s0140-6736(13)61580-9}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings